First-Line Treatment for Thumb Osteoarthritis

Thumb osteoarthritis is a common cause of basal joint pain and functional limitation. Current clinical guidelines converge on a structured first-line pharmacological approach, with agent selection tailored to individual patient tolerability, contraindications, and gastrointestinal risk.

Treatment approach — partial overview

First-line management centres on anti-inflammatory therapy — topical formulations carry strong guideline backing, while oral anti-inflammatory agents are an alternative with gastroprotective cover recommended for patients at elevated gastrointestinal risk; an analgesic option is available for those with contraindications or intolerances, and a supplement with conditional guideline support for hand osteoarthritis is also included in the protocol. Full agent selection, dosing thresholds, and sequencing are in the complete protocol…

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.rdc.2022.03.009.

Topical NSAIDs were uniformly strongly recommended for knee OA by all guidelines and were strongly and conditionally recommended for hand OA by EULAR and ACR/AF, respectively, with the strength of recommendation influenced by practicality of using topical agents on finger joints.

Oral NSAIDs were generally recommended for all sites of OA, but strength of recommendations (conditional/weak versus strong) varied among guidelines, primarily reflecting concerns about adverse effects.

The only guidelines that provided a strong recommendation for acetaminophen were AAOS for the knee and EULAR for the hand.

Acetaminophen is no longer considered "first-line" for OA due to its relative poor efficacy, though it is still an option for those who have contraindications or intolerances to NSAIDs.

Chondroitin, on the other hand, had a conditional recommendation for its use in hand OA by both EULAR and ACR/AF on the basis of a single trial that had low risk of bias, and none of the guidelines recommended chondroitin for other sites with the exception of ESCEO which again provided a strong recommendation for its use in knee OA.

Consider adding proton pump inhibitor or misoprostol in patients at risk for upper gastrointestinal events who require treatment with NSAIDs or COX-2 inhibitors.

View source ↗